PROTALIX BIOTHERAPEUTICS INC (PLX) Stock Fundamental Analysis
NYSEARCA:PLX - NYSE Arca - US74365A3095 - Common Stock - Currency: USD
PLX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. Both the profitability and the financial health of PLX get a neutral evaluation. Nothing too spectacular is happening here. PLX is valued quite cheap, while showing a decent growth score. This is a good combination! This makes PLX very considerable for value investing!
1. Profitability
1.1 Basic Checks
In the past year PLX was profitable.
In the past year PLX had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: PLX reported negative net income in multiple years.
In the past 5 years PLX reported 4 times negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 3.99%, PLX belongs to the best of the industry, outperforming 93.31% of the companies in the same industry.
With an excellent Return On Equity value of 6.79%, PLX belongs to the best of the industry, outperforming 93.84% of the companies in the same industry.
The Return On Invested Capital of PLX (6.87%) is better than 94.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.99% | ||
| ROE | 6.79% | ||
| ROIC | 6.87% |
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PLX has a better Profit Margin (5.49%) than 92.78% of its industry peers.
Looking at the Operating Margin, with a value of 7.34%, PLX belongs to the top of the industry, outperforming 93.66% of the companies in the same industry.
The Gross Margin of PLX (54.46%) is better than 76.76% of its industry peers.
PLX's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.34% | ||
| PM (TTM) | 5.49% | ||
| GM | 54.46% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PLX is destroying value.
PLX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PLX has been increased compared to 5 years ago.
PLX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -1.70, we must say that PLX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.70, PLX perfoms like the industry average, outperforming 56.51% of the companies in the same industry.
There is no outstanding debt for PLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | -1.7 |
ROIC/WACC0.65
WACC10.56%
2.3 Liquidity
PLX has a Current Ratio of 2.34. This indicates that PLX is financially healthy and has no problem in meeting its short term obligations.
PLX has a worse Current ratio (2.34) than 72.01% of its industry peers.
PLX has a Quick Ratio of 1.52. This is a normal value and indicates that PLX is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of PLX (1.52) is worse than 80.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.34 | ||
| Quick Ratio | 1.52 |
3. Growth
3.1 Past
The earnings per share for PLX have decreased strongly by -40.00% in the last year.
PLX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -18.48%.
PLX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.48% yearly.
EPS 1Y (TTM)-40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%228.57%
Revenue 1Y (TTM)-18.48%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%73.74%
3.2 Future
Based on estimates for the next years, PLX will show a very strong growth in Earnings Per Share. The EPS will grow by 431.79% on average per year.
The Revenue is expected to grow by 59.52% on average over the next years. This is a very strong growth
EPS Next Y943.67%
EPS Next 2Y431.79%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year63.84%
Revenue Next 2Y59.52%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 85.00, which means the current valuation is very expensive for PLX.
PLX's Price/Earnings ratio is rather cheap when compared to the industry. PLX is cheaper than 92.25% of the companies in the same industry.
PLX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.29.
With a Price/Forward Earnings ratio of 8.14, the valuation of PLX can be described as very reasonable.
Based on the Price/Forward Earnings ratio, PLX is valued cheaper than 97.36% of the companies in the same industry.
PLX is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.32, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 85 | ||
| Fwd PE | 8.14 |
4.2 Price Multiples
PLX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PLX is cheaper than 93.84% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PLX indicates a rather cheap valuation: PLX is cheaper than 94.72% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.92 | ||
| EV/EBITDA | 35.22 |
4.3 Compensation for Growth
PLX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PLX's earnings are expected to grow with 431.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.09
PEG (5Y)N/A
EPS Next 2Y431.79%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for PLX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.55
-0.06 (-2.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners6.74%
Inst Owner Change0%
Ins Owners7.79%
Ins Owner Change0%
Market Cap198.98M
Analysts80
Price Target14.79 (480%)
Short Float %8.03%
Short Ratio7.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.78%
Min EPS beat(2)-25.74%
Max EPS beat(2)27.3%
EPS beat(4)1
Avg EPS beat(4)-111%
Min EPS beat(4)-248.51%
Max EPS beat(4)27.3%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.77%
Min Revenue beat(2)-3.82%
Max Revenue beat(2)9.37%
Revenue beat(4)2
Avg Revenue beat(4)-11.84%
Min Revenue beat(4)-59.64%
Max Revenue beat(4)9.37%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1.59%
EPS NY rev (3m)-50%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-12.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 85 | ||
| Fwd PE | 8.14 | ||
| P/S | 3.73 | ||
| P/FCF | 26.92 | ||
| P/OCF | 22.94 | ||
| P/B | 4.6 | ||
| P/tB | 4.6 | ||
| EV/EBITDA | 35.22 |
EPS(TTM)0.03
EY1.18%
EPS(NY)0.31
Fwd EY12.28%
FCF(TTM)0.09
FCFY3.72%
OCF(TTM)0.11
OCFY4.36%
SpS0.68
BVpS0.55
TBVpS0.55
PEG (NY)0.09
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.99% | ||
| ROE | 6.79% | ||
| ROCE | 8.2% | ||
| ROIC | 6.87% | ||
| ROICexc | 11.71% | ||
| ROICexgc | 11.71% | ||
| OM | 7.34% | ||
| PM (TTM) | 5.49% | ||
| GM | 54.46% | ||
| FCFM | 13.84% |
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
F-Score5
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 98.31% | ||
| Cap/Sales | 2.4% | ||
| Interest Coverage | 2.56 | ||
| Cash Conversion | 166.14% | ||
| Profit Quality | 252.12% | ||
| Current Ratio | 2.34 | ||
| Quick Ratio | 1.52 | ||
| Altman-Z | -1.7 |
F-Score5
WACC10.56%
ROIC/WACC0.65
Cap/Depr(3y)84.19%
Cap/Depr(5y)86.74%
Cap/Sales(3y)1.83%
Cap/Sales(5y)2.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-40%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%228.57%
EPS Next Y943.67%
EPS Next 2Y431.79%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-18.48%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%73.74%
Revenue Next Year63.84%
Revenue Next 2Y59.52%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-62.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y399.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y758.12%
OCF growth 3YN/A
OCF growth 5YN/A